Medical Breakthroughs Reported by Ivanhoe.com. Click here to go to the homepage.
Be the First to Know. Click here to subscribe FREE!
Search Reports: Use quotation marks around your multi-word search terms in the box below to perform search of Ivanhoe.com.
Advances in health and medicine.Use " marks around search terms
 
What's New
News Flash
Discussion
healthchannelnews
  Alternative Health
Arthritis
Asthma & Allergies
Autism
Breast Cancer
Cancer
Cardiovascular Health
Children's Health
Dental Health
Diabetes
Fertility & Pregnancy
Men's Health
Mental Health
Multiple Sclerosis
Neurological Disorders
Nutrition & Wellness
Orthopedics
Pet Health
Robotics
Seniors' Health
Sports Medicine
Vision
Women's Health
Advances in health and medicine.
Click here to sign up for Medical Alerts!
Click below to access other news from Ivanhoe Broadcast News.
  Click here to get Ivanhoe's Medical Headline RSS feed Click here to listen to Ivanhoe's Medical Podcasts
Useful Links
Play It Again, Please
E-Mail a Friend
Order Books Online
Inside Science
Smart Woman
Advances in health and medicine.
Smart Woman Home
Click here to read the story
Click here to read the story
Click here to read the story
Smart Woman Home
Advances in health and medicine.
Click below to learn about Ivanhoe.
  Awards
About Us
Contact Us
Employment
Feedback
Ivanhoe FAQ
Our TV Partners
Travel Calendar
Advances in health and medicine.
Ivanhoe celebrates 20 years of medical news reporting reaching nearly 80 million TV households each week. Click here to learn more...
Advances in health and medicine.
Marjorie Bekaert Thomas
Publisher/President
Advances in health and medicine.
Advertisement
Cancer Channel
Reported September 26, 2011

New Treatment Reduces Melanoma Growth

(Ivanhoe Newswire) -- Researchers set their eyes on a new treatment! Patients that have been affected by melanoma of the eye, ocular or uveal melanoma, die within an average of two to four months once the disease has spread to the liver due to ineffective treatment.  Only about one in ten patients live for a year.  A recent study has found that with a new treatment patients may be able to reduce the growth of the disease.

James Pingpank, associate professor of surgery at the University of Pittsburgh Cancer Institute, Pennsylvania told the 2011 European Multidisciplinary Cancer Congress that the average length of time that patients survived without the spread of disease in the liver was an average of 8.1 months for those receiving the new treatment, compared to 1.6 months in the group of patients that had been chosen at random to receive alternative care.

The new treatment is called percutaneous hepatic perfusion (PHP) and is designed to saturate the liver with high doses of chemotherapy without affecting the rest of the body.
The study took place in nine U.S clinics, 93 patients were randomly picked to receive PHP or best alternative care (BAC), which was decided by the patient's treatment team.
 
As the study was not designed to show an overall survival benefit, and most of the patients had no other treatment options available to them, patients were allowed to cross over from the BAC group of the study to the PHP group once the benefits of PHP became apparent.
PHP patients had an overall progression-free survival time of 6.1 months compared to 1.6 months in the BAC group.
 
Furthermore, since 51 percent of patients crossed over from the BAC group to the PHP group, survival was not significantly effected between the two groups: 11.4 months on PHP compared to 9.9 months on BAC.  However, those patients who did cross over seemed to do well despite being amongst the sickest, surviving for 9.2 months without the disease progressing in the liver, and 6.5 months without any overall progression of the disease.

For a disease that currently has few treatment options and no change of a cure,  Professor Pingpank was quoted as stating that PHP offers patients extra months of , usually, good quality life.Although the adverse effects of PHP were more severe than BAC, they were short-lived including: low white blood cell count and low platelet count.

 PHP potentially could be used for other cancers that have spread to the liver. "We have demonstrated efficacy in a phase II setting for patients with metastatic neuroendocrine tumors [2], so the application of this technology is likely to expand to other tumor types," Professor Pingpank was quoted as stating.

SOURCE: www.ecco-org.eu, published online September 23, 2011)

To Receive Med Alerts all year click here.

Related Articles in Latest Medical News:

[ Back to Cancer Channel Home ]

MEDICAL ALERT!
Stay up to date on Cancer. We can notify you every time there is a medical breakthrough. Click here to sign up.
EDITOR'S CHOICE
Advertisement

Follow Us On:

Click here to go to Ivanhoe's Twitter page Click here to go to Ivanhoe's Facebook page Click here to go to Ivanhoe's YouTube page

Home | What's New | News Flash | Search/Latest Medical News | E-Mail Medical Alerts!
Ivanhoe FAQ | Privacy Policy | Our TV Partners | Awards | Useful Links | Play It Again, Please
RSS Feeds | Advertising/Sponsorships | Content Syndication | Reprints

Advances in health and medicine.
webdoctor@ivanhoe.com
Copyright © 2014 Ivanhoe Broadcast News, Inc.
2745 West Fairbanks Avenue
Winter Park, Florida 32789
(407) 740-0789

P.O. Box 865
Orlando, Florida 32802

Premium Content in Latest Medical News Denotes Premium Content in Latest Medical News